Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23914870 | 0.84 | — | — | |
| SCHEMBL12056357 | 0.79 | ALDH1A1 (0.39) | CTDSP1 | |
| SCHEMBL12056358 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL12933319 | 0.77 | ALDH1A1 (0.42) | CTDSP1 | |
| SCHEMBL13403845 | 0.77 | ALDH1A1 (0.42) | CTDSP1 | |
| SCHEMBL25875123 | 0.77 | — | — | |
| SCHEMBL10271786 | 0.75 | CTDSP1 (0.33) | CTDSP1 | |
| SCHEMBL16569116 | 0.75 | CTDSP1 (0.30) | CTDSP1 | |
| SCHEMBL26381504 | 0.74 | — | — | |
| SCHEMBL26381491 | 0.72 | GAA (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230265100-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11667643-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | CTDSP1 829/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | CTDSP1 1250/4885 |
| US-20230265100-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | CTDSP1 1250/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | CTDSP1 829/4885 |
| US-11667643-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | CTDSP1 1250/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | CTDSP1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.